Supreme Court dismisses petition seeking removal of GST, customs duty on medicines to cure spinal muscular atrophy
Cure SMA Foundation of India, a parent-led organisation, had approached the court seeking exemption of GST and customs duty on treatment of patients suffering from the disease. However, the court said, “Ultimately it is for the government to take a policy decision whether to completely exempt any drug for treatment of rare diseases from levy of IGST, CGST, SGST or customs duty. No writ of mandamus can be issued for directing the Union to exempt drugs from payment of tax or duty.” (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 9, 2022 Category: Pharmaceuticals Source Type: news
Delta flight attendant tells wheelchair passenger that TSA will make him get off plane ‘with their guns’
When Cory Lee’s Delta flight from Santiago, Chile, landed in Atlanta, Georgia, on Nov. 13, he was looking forward to deplaning after the long trip. The award-winning travel blogger, who is based in Georgia, was diagnosed with spinal muscular atrophy at age 2 and has used a wheelchair for most of…#jetbridge #wheelchair #chair #aislechair #georgia #flight #jet #flightattendants #chile #santiago (Source: Reuters: Health)
Source: Reuters: Health - November 29, 2022 Category: Consumer Health News Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III GRADUATE programme evaluating gantenerumab in early Alzheimer ’s disease
Phase III GRADUATE studies did not meet their primary endpoints of slowing clinical decline in people with early Alzheimer ’sThe level of beta-amyloid removal by gantenerumab was lower than expectedTopline data will be presented at the Clinical Trials on Alzheimer ’s Disease (CTAD) ConferenceRoche is committed to the Alzheimer ’s community and will continue to develop novel diagnostics and potential treatments for Alzheimer’sBasel, 14 November 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from the GRADUATE I and II studies evaluating gantenerumab in people with mild cognitive impairment (MCI) du...
Source: Roche Investor Update - November 14, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III GRADUATE programme evaluating gantenerumab in early Alzheimer ’s disease
Phase III GRADUATE studies did not meet their primary endpoints of slowing clinical decline in people with early Alzheimer ’sThe level of beta-amyloid removal bygantenerumab was lower than expectedTopline data will be presented at the Clinical Trials on Alzheimer ’s Disease (CTAD) ConferenceRoche is committed to the Alzheimer ’s community and will continue to develop novel diagnostics and potential treatments for Alzheimer ’sBasel, 14 November 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from the GRADUATE I and II studies evaluating gantenerumab in people with mild cognitive impairment (MCI) du...
Source: Roche Investor Update - November 14, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III GRADUATE programme evaluating gantenerumab in early Alzheimer ’s disease
Phase III GRADUATE studies did not meet their primary endpoints of slowing clinical decline in people with early Alzheimer ’sThe level of beta-amyloid removal bygantenerumab was lower than expectedTopline data will be presented at the Clinical Trials on Alzheimer ’s Disease (CTAD) ConferenceRoche is committed to the Alzheimer ’s community and will continue to develop novel diagnostics and potential treatments for Alzheimer ’sBasel, 14 November 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from the GRADUATE I and II studies evaluating gantenerumab in people with mild cognitive impairment (MCI) du...
Source: Roche Media News - November 14, 2022 Category: Pharmaceuticals Source Type: news
Early treatment with Roche's OCREVUS leads to reduced disease progression and healthcare costs; nine-year safety data reinforce favourable benefit-risk profile
77% of early-stage relapsing-remitting multiple sclerosis (RRMS) patients who had not received prior treatment achieved no evidence of disease activity (NEDA) at two yearsInitiation of OCREVUS as first-line treatment reduces relapses,hospitalisations and costs compared with using OCREVUS in second-line settingNine-year long-term safety data for OCREVUS further reinforcefavourable benefit-risk profile; more than 250,000 people have been treated globallyPregnancy outcomes reported for more than 2,000 women with multiple sclerosis (MS) treated with OCREVUS do not suggest an increased risk of adverse pregnancy and infant outco...
Source: Roche Media News - October 26, 2022 Category: Pharmaceuticals Source Type: news
Early treatment with Roche's OCREVUS leads to reduced disease progression and healthcare costs; nine-year safety data reinforce favourable benefit-risk profile
77% of early-stage relapsing-remitting multiple sclerosis (RRMS) patients who had not received prior treatment achieved no evidence of disease activity (NEDA) at two yearsInitiation of OCREVUS as first-line treatment reduces relapses,hospitalisations and costs compared with using OCREVUS in second-line settingNine-year long-term safety data for OCREVUS further reinforcefavourable benefit-risk profile; more than 250,000 people have been treated globallyPregnancy outcomes reported for more than 2,000 women with multiple sclerosis (MS) treated with OCREVUS do not suggest an increased risk of adverse pregnancy and infant outco...
Source: Roche Investor Update - October 26, 2022 Category: Pharmaceuticals Source Type: news
Roche to present new OCREVUS (ocrelizumab) data in multiple sclerosis and continued research into neuromyelitis optica spectrum disorder at ECTRIMS 2022
OCREVUS data will show significant benefit on slowing disease activity and progression in patients with treatment-naive early-stage relapsing-remitting multiple sclerosis (RRMS)Largest pregnancy safety data across anti-CD20 medicines for OCREVUS in multiple sclerosis (MS)Nine-year safety data for OCREVUS reinforces itsfavourable benefit-risk profileNew research demonstrates impact of misdiagnosis and delay of starting treatment in NMOSDBasel, 19 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS ® (ocrelizumab) data and continued research into neuromyelitis optica spectrum disorder (NMOSD) ...
Source: Roche Media News - October 19, 2022 Category: Pharmaceuticals Source Type: news
Roche to present new OCREVUS (ocrelizumab) data in multiple sclerosis and continued research into neuromyelitis optica spectrum disorder at ECTRIMS 2022
OCREVUS data will show significant benefit on slowing disease activity and progression in patients with treatment-naive early-stage relapsing-remitting multiple sclerosis (RRMS)Largest pregnancy safety data across anti-CD20 medicines for OCREVUS in multiple sclerosis (MS)Nine-year safety data for OCREVUS reinforces itsfavourable benefit-risk profileNew research demonstrates impact of misdiagnosis and delay of starting treatment in NMOSDBasel, 19 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS ® (ocrelizumab) data and continued research into neuromyelitis optica spectrum disorder (NMOSD) ...
Source: Roche Investor Update - October 19, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche records solid results for the first nine months of 2022
Group salesup 2%[1] at constant exchange rates (CER) and 1% in Swiss francs; as expected, significantly lower COVID-19-related sales in both divisions in the third quarterSales in the Pharmaceuticals Divisionat the previous year ’s level with significantly lower sales of COVID-19-related products (Ronapreve and Actemra/RoActemra) and losses to biosimilars, offset by strong growth of newer medicinesSales in the Diagnostics Divisionrise 6%; base business remains strong; as expected, demand for COVID-19 tests sharply down in third quarterHighlights in the third quarter:EU approval forVabysmo (severe eye diseases)US approval...
Source: Roche Investor Update - October 18, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche records solid results for the first nine months of 2022
Basel, 18 October 2022Group salesup 2%1 at constant exchange rates (CER) and 1% in Swiss francs; as expected, significantly lower COVID-19-related sales in both divisions in the third quarterSales in the Pharmaceuticals Divisionat the previous year ’s level with significantly lower sales of COVID-19-related products (Ronapreve and Actemra/RoActemra) and losses to biosimilars, offset by strong growth of newer medicinesSales in the Diagnostics Divisionrise 6%; base business remains strong; as expected, demand for COVID-19 tests sharply down in third quarterHighlights in the third quarter:EU approval forVabysmo (severe eye ...
Source: Roche Media News - October 18, 2022 Category: Pharmaceuticals Source Type: news
Positive new data for Roche ’s Evrysdi in largest trial ever undertaken in patients with previously-treated spinal muscular atrophy (SMA)
New two-year Evrysdi data show improvement or maintenance of motor function in people with SMA, a progressive neuromuscular disease that can be fatalThe JEWELFISH study enrolled the broadest and most diverse patient population ever studied in an SMA trialLonger-term safety data consistent with that previously seen in earlier trials and low study drop-out rateEvrysdi has proven efficacy in babies, children and adults, with more than 7,000 patients treated to date worldwideBasel, 12 October 2022- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new two-year data from the JEWELFISH study evaluating Evrysdi ® (risdiplam) in...
Source: Roche Investor Update - October 12, 2022 Category: Pharmaceuticals Source Type: news
Positive new data for Roche ’s Evrysdi in largest trial ever undertaken in patients with previously-treated spinal muscular atrophy (SMA)
New two-year Evrysdi data show improvement or maintenance of motor function in people with SMA, a progressive neuromuscular disease that can be fatalThe JEWELFISH study enrolled the broadest and most diverse patient population ever studied in an SMA trialLonger-term safety data consistent with that previously seen in earlier trials and low study drop-out rateEvrysdi has proven efficacy in babies, children and adults, with more than 7,000 patients treated to date worldwideBasel, 12 October 2022- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new two-year data from the JEWELFISH study evaluating Evrysdi ® (risdiplam) in...
Source: Roche Media News - October 12, 2022 Category: Pharmaceuticals Source Type: news
Roche to present new data from its expanding neuromuscular disease portfolio at World Muscle Society 2022
New positive data fromEvrysdi, a treatment for spinal muscular atrophy (SMA), a progressive neuromuscular disease that can be fatalData from the gene therapyprogramme forDuchenne muscular dystrophy (DMD), a progressive disease that leads to premature death, reinforce confidence in the most advanced Phase 3 study currently underwayStudy designs of two new trials ingeneralised myasthenia gravis (gMG), a rare chronic autoimmune disease, andfacioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorderBasel, 05 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from its industry-leading n...
Source: Roche Media News - October 5, 2022 Category: Pharmaceuticals Source Type: news
Roche to present new data from its expanding neuromuscular disease portfolio at World Muscle Society 2022
New positive data fromEvrysdi, a treatment for spinal muscular atrophy (SMA), a progressive neuromuscular disease that can be fatalData from the gene therapyprogramme forDuchenne muscular dystrophy (DMD), a progressive disease that leads to premature death, reinforce confidence in the most advanced Phase 3 study currently underwayStudy designs of two new trials ingeneralised myasthenia gravis (gMG), a rare chronic autoimmune disease, andfacioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorderBasel, 05 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from its industry-leading n...
Source: Roche Investor Update - October 5, 2022 Category: Pharmaceuticals Source Type: news
